Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly

Vaccine

Volumn 25, Issue 13, 2007, Pages 2445-2450

  Örtqvist, Å ^a,b   Henckaerts, I ^c   Hedlund, J ^b   Poolman, J ^c  

^a Department of Communicable Diseases Control and Prevention ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Antibody concentration; Opsonophagocytic activity; Pneumococcal vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNIZATION; LOBAR PNEUMONIA; MALE; PRIORITY JOURNAL; SEROTYPE; TREATMENT FAILURE; VACCINATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 33847793775     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.018     Document Type: Article

References (25)

1. Watson D.A., and Musher D.M. Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916. Infect Immun 58 9 (1990) 3135-3138
2. Saeland E., Jakobsen H., Ingolfsdottir G., Sigurdardottir S.T., and Jonsdottir I. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 183 2 (2001) 253-260
3. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
4. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. 927 (Annex) WHO Tech. Rep. Ser. 2005. pp. 64.
5. Concepcion N.F., and Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8 2 (2001) 266-272
6. Henckaerts I., Goldblatt D., Ashton L., and Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 13 3 (2006) 356-360
7. Musher D.M., Groover J.E., Rowland J.M., Watson D.A., Struewing J.B., Baughn R.E., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 17 1 (1993) 66-73
8. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21 23 (2003) 3265-3272
9. Musher D.M., Watson D.A., and Baughn R.E. Genetic control of the immunologic response to pneumococcal capsular polysaccharides. Vaccine 19 6 (2000) 623-627
10. Poolman J.T. Pneumococcal vaccine development. Expert Rev Vaccines 3 5 (2004) 597-604
11. Goldblatt D., Hussain M., Andrews N., Ashton L., Virta C., Melegaro A., et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 192 3 (2005) 387-393
12. Musher D.M., Chapman A.J., Goree A., Jonsson S., Briles D., and Baughn R.E. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 154 2 (1986) 245-256
13. Yu X., Gray B., Chang S., Ward J.I., Edwards K.M., and Nahm M.H. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 180 5 (1999) 1569-1576
14. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 29 2 (1999) 281-288
15. Kolibab K., Smithson S.L., Rabquer B., Khuder S., and Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 73 11 (2005) 7465-7476
16. Smithson S.L., Kolibab K., Shriner A.K., Srivastava N., Khuder S., and Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable light chain repertoire. Infect Immun 73 11 (2005) 7477-7484
17. Ortqvist A., Hedlund J., Burman L.A., Elbel E., Hofer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351 9100 (1998) 399-403
18. Musher D.M., Groover J.E., Graviss E.A., and Baughn R.E. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 22 1 (1996) 165-167
19. Henckaerts I., Durant N., De Grave D., Schuerman L., and Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25 (2007) 2518-2527
20. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Andersson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4 4 (1997) 415-422
21. Musher D.M., Phan H.M., Watson D.A., and Baughn R.E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. J Infect Dis 182 1 (2000) 158-167
22. Kruetzmann S., Rosado M.M., Weber H., Germing U., Tournilhac O., Peter H.H., et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197 7 (2003) 939-945
23. Carsetti R., Rosado M.M., Donnanno S., Guazzi V., Soresina A., Meini A., et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 115 2 (2005) 412-417
24. Hendley J.O., Sande M.A., Stewart P.M., and Gwaltney Jr. J.M. Spread of Streptococcus pneumoniae in families. Part I. Carriage rates and distribution of types. J Infect Dis 132 1 (1975) 55-61
25. Musher D.M., Groover J.E., Reichler M.R., Riedo F.X., Schwartz B., Watson D.A., et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin Infect Dis 24 3 (1997) 441-446